1. Martinez JR, Grantham JJ. Polycystic kidney disease: etiology, pathogenesis, and treatment. Dis Mon. 1995; 41:693–765.
2. Luciano RL, Dahl NK. Extra-renal manifestations of autosomal dominant polycystic kidney disease (ADPKD): considerations for routine screening and management. Nephrol Dial Transplant. 2014; 29:247–254.
3. Handa SP. Cardiovascular manifestations of autosomal dominant polycystic kidney disease in young adults. Clin Invest Med. 2006; 29:339–346.
4. Torres VE. Extrarenal manifestations of autosomal dominant polycystic kidney disease. Am J Kidney Dis. 1999; 34:xlv–xlviii.
5. Rahbari-Oskoui F, Mittal A, Mittal P, Chapman A. Renal relevant radiology: radiologic imaging in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2014; 9:406–415.
6. Ecder T, Schrier RW. Cardiovascular abnormalities in autosomal-dominant polycystic kidney disease. Nat Rev Nephrol. 2009; 5:221–228.
7. Griffin MD, Torres VE, Grande JP, Kumar R. Vascular expression of polycystin. J Am Soc Nephrol. 1997; 8:616–626.
8. Nauser TD, Stites SW. Diagnosis and treatment of pulmonary hypertension. Am Fam Physician. 2001; 63:1789–1798.
9. Parvari R, Levitas A. The mutations associated with dilated cardiomyopathy. Biochem Res Int. 2012; 2012:639250.
10. Paavola J, Schliffke S, Rossetti S, Kuo IY, Yuan S, Sun Z, et al. Polycystin-2 mutations lead to impaired calcium cycling in the heart and predispose to dilated cardiomyopathy. J Mol Cell Cardiol. 2013; 58:199–208.